(Q50559019)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Benjamin Krämer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Christian Körner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Hans Dieter Nischalke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

author name string

Martin Hennenberg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Zaki Kohistani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Christian Stark

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Sabine Klein

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Michaela Granzow

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Hans-Peter Fischer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Jörg Heller

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Tilman Sauerbruch

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

4 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

published in

Laboratory Investigation

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

241-251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20921950%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/labinvest.2010.148

15 February 2020

exact match

0 references

cites work

Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sorafenib-induced liver failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

Therapy for portal hypertension: What is our pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148

inferred from DOI database lookup

7 January 2021

based on heuristic

Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.148